COVID-19

Testing Information and News for Individuals, Healthcare Providers, Payers, and Organizations

Let’s determine which COVID-19 test is right for you.

Labcorp OnDemand

Get a Pixel by Labcorp COVID-19 Home Test Collection Kit at $0 Upfront Cost for Eligible Individuals With Insurance

Find out if you currently have COVID-19 without leaving home.

CONVENIENT COVID-19 TESTING OPTIONS

Keep yourself and your loved ones safe by testing for COVID-19

With over 50 million COVID-19 tests performed since the start of the pandemic, our tests continue to detect all of the variant changes being tracked by the CDC, including the Delta variant.

There are four ways to get the trusted Labcorp COVID-19 PCR test.

Tracking COVID-19 Variants

Labcorp has been regularly tracking variants of the virus throughout the pandemic. The sensitivity of our PCR test is not impacted by these variants. We have been working with the Centers for Disease Control and Prevention (CDC) to provide sequencing of samples of SARS-CoV-2, the virus that causes COVID-19. Our tests remain effective against variants like Omicron and Delta. This is because they are designed to identify segments of the genetic code that are the least likely to mutate. For more information on variants, see our Viral Variation 101 post or read our Guide to Variants.

Total number of samples sequenced

402,000 as of June 30, 2022

Data covers the U.S. including the District of Columbia and Puerto Rico

Labcorp PCR Test performance confirmed

Alpha (B.1.1.7, Q.1-Q.8)

Beta (B.1.351, B.1.351.2, B.1.351.3)

Delta (B.1.617.2)

Epsilon (B.1.427, B.1.429)

Eta (B.1.525)

Gamma (P.1, P.1.1, P.1.2) 

Iota (B.1.526)

Kappa (B.1.617.1)

Lambda (C.37)

Mu (B.1.621)

Omicron (B.1.1.529, BA.2, BA.4, BA.5)

Zeta (P.2)

For more information visit US COVID-19 Cases Caused by Variants on the CDC website. 

Labcorp's COVID-19 Testing Stats

1-2 Days

COVID-19 PCR Testing

Average Time to Result

From Specimen Pickup

70.6M

COVID-19 PCR Testing

Molecular Tests Performed

8.9M

COVID-19 Antibody Testing

Antibody Tests Performed

Stats updated as of June 30, 2022. COVID-19 volumes are U.S. and Canada volumes and are consistent with the figures provided in the company’s quarterly financial results. Prior volumes published on the website were U.S. only. Future COVID-19 test volumes will be updated quarterly after the release of Labcorp’s quarterly earnings results.


How can I make a difference?

COVID-19 Clinical Trials Connect

Labcorp Drug Development is running multiple COVID-19 research studies and invites you to help in the fight against COVID-19.


Get Tested

See How Labcorp Performs the COVID-19 Test

You can get tested through your healthcare provider, have them request a Labcorp COVID-19 home collection kit, or request one yourself by visiting Labcorp OnDemand.


Latest & Previous News

Jun 14 2022

Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages

BURLINGTON, N.C.,  June 14, 2022 — On Friday, June 10, 2022, Labcorp, a global life sciences company, received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its VirSeq SARS-CoV-2 NGS (next-generation sequencing) Test on the PacBio Sequel II sequencing system.

Read more about Media Statement: Labcorp Receives FDA Emergency Use Authorization for First COVID-19 Test to Identify Specific SARS-CoV-2 Lineages

Previous News Releases and Media Statements

May 18 2022

Labcorp Receives Emergency Use Authorization for First Non-Prescription At-Home Collection Kit for Combined COVID-19, Flu and RSV Detection

BURLINGTON, N.C.,  May 18, 2022 — Labcorp (NYSE: LH), a leading global life sciences company, today announced the receipt of Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined at-home collection kit available that simultaneously detects COVID-19, influenza A/B and respiratory syncytial virus (RSV), a common but contagious respiratory virus often seen in children. 

Read more about Labcorp Receives Emergency Use Authorization for First Non-Prescription At-Home Collection Kit for Combined COVID-19, Flu and RSV Detection
Nov 30 2021

Labcorp Now Offers Observed Collection for COVID-19 PCR Testing in Over 500 Locations Nationwide, with Plans to Expand to More Than 1,000 Locations

BURLINGTON, N.C., Nov. 30, 2021 — Labcorp (NYSE: LH), a global life sciences company, is now offering observed self-collection for COVID-19 PCR testing in more than 500 of its patient service centers (PSCs) nationwide for people without symptoms or known exposure. By mid-December, the company plans to further expand the COVID-19 PCR test collection service to over 1,000 locations. 

Read more about Labcorp Now Offers Observed Collection for COVID-19 PCR Testing in Over 500 Locations Nationwide, with Plans to Expand to More Than 1,000 Locations
Oct 1 2021

Labcorp Receives Emergency Use Authorization for At Home Collection Kit for Combined COVID-19 and Flu Detection

BURLINGTON, N.C., Oct. 1, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a combined home collection kit that detects COVID-19 and influenza A/B simultaneously in individuals as young as 2 years of age. The kit will be available at no upfront cost to those who meet clinical guidelines, which may include experiencing symptoms, being exposed to someone with COVID-19 or if asked to be tested by a health care provider. 

Read more about Labcorp Receives Emergency Use Authorization for At Home Collection Kit for Combined COVID-19 and Flu Detection
Jul 1 2021

Labcorp Extends COVID-19 Genomic Sequencing Work With The CDC

BURLINGTON, N.C., June 30, 2021 — Labcorp (NYSE: LH), a leading global life sciences company, today announced the extension of its work with the U.S. Centers for Disease Control and Prevention (CDC) to help identify and monitor variants of SARS-CoV-2, the virus that causes COVID-19. 

Read more about Labcorp Extends COVID-19 Genomic Sequencing Work With The CDC
Jun 22 2021

Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance

Molecular Loop Biosciences, Inc. , a company redefining the simplicity of targeted sequencing, announced today that its SARS-CoV-2 Research Sequencing Panel has been deployed by Labcorp (NYSE: LH), a leading global life sciences company, to help sequence thousands of complete coronavirus genomes each week from positive patient samples. This sequencing is being performed as part of a U.S. Centers for Disease Control and Prevention (CDC) effort to identify and track the spread of SARS-CoV-2 variants throughout the country.

Read more about Labcorp Adopts Molecular Loop SARS-CoV-2 Research Sequencing Panel for Large-Scale Viral Surveillance
Jun 16 2021

NCDHHS Expands Home Testing Program to All Eligible North Carolinians

The North Carolina Department of Health and Human Services today announced the state is expanding availability of its at-home COVID-19 test collection. Any North Carolina resident may receive a Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit that is shipped overnight directly to their homes at no cost. Tests can be used on people age 2 and up.

Read more about NCDHHS Expands Home Testing Program to All Eligible North Carolinians